Morvus Technology
Carmarthen
About Morvus Technology
Morvus Technology Ltd., a pharmaceutical company, engages in the discovery, development, and commercialization of drugs and technologies in the oncology field. Its clinical candidates include MTL-005, a therapy for cancers treated with conventional radiotherapy; MTL-007, a novel anti-cancer prodrug; and MTL-003, an anti-angiogenic cancer therapy. The company's research portfolio comprises MorTar platform technology that identifies new proteins and genes that share the ability to inhibit apoptosis; HAI-X, an anti-angiogenic treatment for prostate cancer; and MorGen, a novel prodrug-activating system. The company also engages in the development of anti-cancer treatments using genetic modification techniques. In addition, it offers MorAnt, an anti-parasitic drug; and MorRid, a rodenticide. Morvus Technology Ltd. was founded in 2004 and is based in Carmarthen, the United Kingdom.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $3.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2010)
- Website: morvus.com
- Phone: 44 15 5866 8111
Industries & Categories
Biotechnology, Genetics, Oncology
Social Profiles
Canonical: https://fsome.com/organization/morvus-technology-2658383 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.